Bioventus (BVS) Cost of Revenue (2020 - 2026)

Bioventus (BVS) has 7 years of Cost of Revenue data on file, last reported at $41.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 1.22% year-over-year to $41.3 million; the trailing twelve-month figure through Mar 2026 stood at $180.4 million (down 2.36% YoY), and the FY2025 full-year result was $179.9 million, down 2.77% from the prior year.
• Cost of Revenue for Q1 2026 stood at $41.3 million, down from $49.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $51.6 million in Q4 2022 and bottomed at $40.8 million in Q1 2025.
• The 5-year median for Cost of Revenue is $45.1 million (2023), against an average of $45.4 million.
• The widest annual swing landed in 2022, when Cost of Revenue jumped 87.15%; it then fell 9.0% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $51.6 million in 2022, then retreated by 4.89% to $49.1 million in 2023, then climbed by 3.79% to $51.0 million in 2024, then declined by 3.66% to $49.1 million in 2025, then dropped by 15.88% to $41.3 million in 2026.
• The last three Cost of Revenue figures came in at $41.3 million (Q1 2026), $49.1 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.

Peer Comparison